Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: a randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219

Lung cancer is the leading cause of world-wide cancer related mortality [1]. With the introduction of new agents such as tyrosine kinase inhibitors and checkpoint inhibitors, the treatment paradigm for patients with metastatic non-small cell lung cancer (NSCLC) is rapidly changing [2,3]. Despite significant advances, prognosis for lung cancer patients is still poor and new treatment approaches are necessary.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research